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Abstract
Objective To determine the efficacy and safety of enoxaparin compared
with unfractionated heparin during percutaneous coronary intervention.
Design Systematic review and meta-analysis.
Data sources Medline and Cochrane database of systematic reviews,
January 1996 to May 2011.
Study selection Randomised and non-randomised studies comparing
enoxaparin with unfractionated heparin during percutaneous coronary
intervention and reporting on both mortality (efficacy end point) and
major bleeding (safety end point) outcomes.
Data extraction Sample size, characteristics, and outcomes, extracted
independently and analysed.
Data synthesis 23 trials representing 30 966 patients were identified,
including 10 243 patients (33.1%) undergoing primary percutaneous
coronary intervention for ST elevation myocardial infarction, 8750 (28.2%)
undergoing secondary percutaneous coronary intervention after
fibrinolysis, and 11 973 (38.7%) with non-ST elevation acute coronary
syndrome or stable patients scheduled for percutaneous coronary
intervention. A total of 13 943 patients (45.0%) received enoxaparin and
17 023 (55.0%) unfractionated heparin. Enoxaparin was associated with
significant reductions in death (relative risk 0.66, 95% confidence interval
0.57 to 0.76; P<0.001), the composite of death or myocardial infarction
(0.68, 0.57 to 0.81; P<0.001), and complications of myocardial infarction
(0.75, 0.6 to 0.85; P<0.001), and a reduction in incidence of major
bleeding (0.80, 0.68 to 0.95; P=0.009). In patients who underwent primary
percutaneous coronary intervention, the reduction in death (0.52, 0.42
to 0.64; P<0.001) was particularly significant and associated with a
reduction in major bleeding (0.72, 0.56 to 0.93; P=0.01).
Conclusion Enoxaparin seems to be superior to unfractionated heparin
in reducing mortality and bleeding outcomes during percutaneous
coronary intervention and particularly in patients undergoing primary
percutaneous coronary intervention for ST elevation myocardial infarction.
Introduction
Theuseofunfractionatedheparinduringpercutaneouscoronary
intervention is limited by its unpredictable effect, the need for
close monitoring, and the uncertainty around optimal levels of
activated clotting time.
1-4 Moreover, the drug exhibits
prothrombotic properties related to platelet activation, poor
control of von Willebrand factor release, and rebound of
thrombin generation after discontinuation.
5 6 Despite these
limitations and the absence of relevant randomised placebo
controlled trials, anticoagulation during elective and primary
percutaneous coronary intervention has traditionally been
supportedbyunfractionatedheparin,basedlargelyonhistorical
practice. The current updated guidelines for anticoagulation in
patients requiring percutaneous coronary intervention for ST
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Characteristics of included studies
Death or myocardial infarction in participants
Complications of myocardial infarction (or myocardial infarction) in participants
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Research
RESEARCHsegment elevation myocardial infarction produced by the
AmericanCollegeofCardiology,AmericanHeartAssociation,
and Society of Cardiac Angiography and Intervention as well
as guidelines from the Task Force on Myocardial
Revascularization of the European Society of Cardiology
continue to afford unfractionated heparin a class 1
recommendation for this indication, despite limited supporting
evidence (level of evidence C).
7 8
Enoxaparin is the leading low molecular weight heparin with
thelargestvolumeofpublishedinformationonuseinthesetting
of percutaneous coronary intervention. It provides predictable
anticoagulation without the need for monitoring
9 10 and it can
be administered predominantly by subcutaneous injection, as
in the management of non-ST elevation acute coronary
syndromes and ST elevation myocardial infarction treated with
thrombolysis, in both cases with a scheduled invasive strategy
(American College of Cardiology and American Heart
Association class IIa and I, respectively). Enoxaparin can also
be used with intravenous injections for immediate
anticoagulation in patients undergoing primary percutaneous
coronary intervention or elective percutaneous coronary
intervention,asshownrecentlyinseveralrandomisedstudies.
11-14
Althoughstudieshaveevaluatedenoxaparinduringpercutaneous
coronary intervention in several clinical settings,
15-33 none was
powered for mortality.
We pooled the data from all the studies that compared
enoxaparin with unfractionated heparin during percutaneous
coronary intervention to gain sufficient power to evaluate
potential differences in mortality and safety.
Methods
Two researchers (JS and GM) searched PubMed and the
Cochrane database of systematic reviews from January 1996 to
May2011usingthesearchterms“enoxaparin”,“unfractionated
heparin”, “angioplasty”, and “percutaneous coronary
intervention”. In addition, we contacted experts in the specialty
andreviewedabstractsfromselectedmajorcardiologyscientific
meetings (American Heart Association, American College of
Cardiology,EuropeanSocietyofCardiology,andTranscatheter
CardiovascularTherapeutics).Themeta-analysisincludedcohort
studies and clinical trials that compared the efficacy and safety
of enoxaparin with unfractionated heparin among patients
undergoingprimary,secondary(post-fibrinolysis),orscheduled
percutaneous coronary intervention according to a predefined
protocol. We restricted our analysis to trials that met all of the
followinginclusioncriteria:patientswithcoronaryheartdisease
undergoing percutaneous coronary intervention, considering
the whole study population or at least a predominant subset of
this population; a control group using unfractionated heparin
forcomparisonwithenoxaparin;andpublicationsreportingdata
at least on mortality and major bleeding. To focus on the direct
comparison of enoxaparin with unfractionated heparin, we
excludedstudiesthatusedalowmolecularweightheparinother
thanenoxaparin,withtheexceptionofonestudyinwhichother
low molecular weight heparins were used in a few of the
patients.
34
A total of 229 studies were identified as potentially relevant
and were screened for inclusion. Of the 34 studies that fulfilled
the inclusion criteria and were screened in detailed, we
subsequently excluded 11 because they did not include data on
efficacy outcomes
35 did not include data on the percutaneous
coronary intervention subgroup,
36-41 published details of the
percutaneous coronary intervention subgroup in a separate
article,
42 43orstudiedalowmolecularweightheparinotherthan
enoxaparin.
44 45 From the 23 studies remaining for the analysis,
two reviewers (JS and OB) independently extracted outcome
data and recorded the information on a standardised case report
form.Whenavailableweextractedthefollowingdatafromeach
trial:yearofpublication,trialdesign,populationcharacteristics,
number of patients (per group), dose and mode of enoxaparin
administered,doseofunfractionatedheparin,useofantiplatelet
drugs(aspirin,thienopyridine,andplateletglycoproteinIIb/IIIa
inhibitors),durationoffollow-up,efficacyendpoints,andsafety
end points (see web extra table).
Assessment and reporting risk of bias in
included studies
Two independent reviewers determined the quality score of
non-randomised studies and subanalysis and retrospective
analysis of randomised controlled trials according to the
Newcastle-Ottawa scale for cohort studies (www.ohri.ca/
programs/clinical_epidemiology/oxford.htm). We also carried
out a validity assessment according to the Cochrane
Collaboration’s tool for assessing risk of bias. Randomised
clinical trials were graded based on sequence generation,
allocation concealment, blinding, incomplete outcome data,
selectiveoutcomereporting,andothersourcesofbias.Foreach
trial we summarised the global assessment of risk of bias as
low,unclear,orhigh.Weentereddataintoacentraliseddatabase
for analysis and resolved discrepancies by consensus of two
authors (JS and OB). If additional data or clarification was
necessary we contacted the study authors. When necessary,
researchassociateswiththerelevantlanguagehelpedtointerpret
non-English manuscripts.
24
Endpoint definitions
The main objective of this study was to evaluate the impact of
enoxaparin and unfractionated heparin on mortality (main
efficacy end point) and major bleeding (main safety end point)
during percutaneous coronary intervention. We considered all
cause mortality except in studies where only cardiovascular
mortality was reported. The bleeding definitions used for this
analysis were those corresponding to the main safety end point
of each study (see web extra table). Other efficacy end points
analysed were the composite ischaemic end point of death or
myocardialinfarctionandcomplicationsofmyocardialinfarction
(orpost-proceduremyocardialinfarctionwhenthiswastheonly
reportedcomplication)asdefinedineachstudy.Majorbleeding
was the main safety end point, although we also collected and
analysed data on minor bleeding. We considered all end points
at the longest follow-up available in each study. Firstly, we
carried out a global meta-analysis of all the studies, including
all patients after percutaneous coronary intervention regardless
of the clinical presentation. Secondly, we carried out a
meta-analysis for the same end points, restricting the analyses
to predefined types of percutaneous coronary intervention:
primary, secondary (post-fibrinolysis), and scheduled (patients
with non-ST elevation acute coronary syndromes or stable
patients).
Statistical analysis
Fromeachpublicationweobtainedtherawnumbersofpatients
experiencingtheoutcomesofinterestamongallpatientsineach
treatment group. We obtained the common effect calculation
by analysis of all patients. Using a random model we carried
out several analyses to obtain a global estimation of the
treatmenteffectandtominimiseheterogeneitybetweengroups.
We used the EasyMa software (Department of Clinical
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Lyon, France) to calculate relative risks with 95% confidence
intervals.
46 An α risk of 5% was used. Finally, the number of
patientsneededtotreat(NNT)toavoidoneeventwascalculated
using the overall weighted risk difference: NNT=1/(absolute
risk difference).
Confirmatory evaluation of potential bias
Wecarriedoutaconfirmatoryanalysisusingthe“meta”package
of R software (R version 2.13.0, R Foundation for Statistical
Computing)andarcsinetransformation.Thisanalysisaccounts
for heterogeneity, particularly when effect sizes are small and
heterogeneity is high, and allows inclusion of trials with zero
events in each arm.
Subgroup analysis and investigation of
heterogeneity
Although the random effect model accommodated variability
among studies, we examined the extent of heterogeneity in the
individual trials. We used the Q Cochran test to look for
heterogeneity between groups, with heterogeneity tests set at
0.1.
47 Potential small study bias or publication bias (that is, the
likelihood of small yet nominally significant studies being
published selectively) was examined by visual inspection of
constructed funnel plots and analytically using Egger’s test.
48
Egger’s method plots linearly the standard normal deviate
(naturallogarithmofrelativerisk/standarderror(SE)ofrelative
risk) and precision (1/SE of relative risk) as independent
variables,withtestresultsbasedonthePvalueoftheregression
constant.
Sensitivity analysis
We carried out a sensitivity analysis by removing each study
inturnfromtheoveralldatatoevaluatetheinfluenceofasingle
studyonthepooledanalysisandbyrestrictingthemeta-analysis
to several subgroups: patients with ST elevation myocardial
infarction undergoing percutaneous coronary intervention
(primary or secondary), published (full length) studies, small
(<500patients)versuslargestudies(≥500patients),intravenous
versus subcutaneous enoxaparin, and high quality (randomised
controlled trials) or low quality studies (registry based).
Results
Twenty three trials, totalling 30 966 patients, met the inclusion
criteria (fig 1⇓). Twelve randomised controlled trials and 11
non-randomisedtrials(includingfoursubanalysesofrandomised
controlled trials) compared enoxaparin with unfractionated
heparinduringpercutaneouscoronaryintervention.Theaverage
follow-up of the studies was 2.4 months, but most (n=19) had
only short term follow-up (in hospital or at 30 days). A total of
13943patients(45.0%)receivedenoxaparinand17023(55.0%)
unfractionated heparin. In seven trials, totalling 10 243 patients
(33.1%),primarypercutaneouscoronaryinterventionwascarried
out for ST elevation myocardial infarction; in three trials,
totalling 8750 patients (28.2%), percutaneous coronary
interventionwascarriedoutafterinitialreperfusionwithlytics;
andin13trials,totalling11973patients(38.7%),percutaneous
coronary intervention was carried out in an elective setting. In
15 of these trials, enoxaparin was used as an intravenous bolus
just before percutaneous coronary intervention; at a low dose
(0.5 mg/kg) in four studies and at a higher dose (0.75 mg/kg or
1 mg/kg) in 12 studies (including the 0.75 mg/kg arm of the
STEEPLE trial). In six trials, patients underwent percutaneous
coronary intervention under a regimen of enoxaparin
administered subcutaneously, and in two trials
20 33 no mention
was made of the enoxaparin dose or mode in which it was
administered. The dose range for unfractionated heparin was
60 to 100 IU/kg bolus according to the concomitant use of
platelet glycoprotein IIb/IIIa inhibitors or not, with further
adjustments based on measurement of activated clotting time.
Table 1⇓ outlines the details of the trials, the settings of the
percutaneous coronary intervention, and length of follow-up
(see web extra table for anticoagulation protocols, concomitant
use of antiplatelet therapies, and major baseline characteristics
of each study). Within each randomised trial, the baseline
characteristics of patients treated with enoxaparin or with
unfractionated heparin were similar, but some of the main
characteristics in the registry based studies differed (see web
extra table).
Summary of end points
Figure 2⇓ summarises all studied end points for the total
population of the meta-analysis, as well as the subgroup of
patientsundergoingprimarypercutaneouscoronaryintervention.
The Cochrane P value for heterogeneity is included.
Mortality
In the overall cohort of patients (n=30 966), enoxaparin was
associated with a 34% relative risk reduction (0.66, 95%
confidenceinterval0.58to0.77;P<0.001)anda1.66%absolute
risk reduction of mortality (NNT=60; fig 3⇓). Heterogeneity
between trials was not significant (P=0.46) and evidence of
publication bias using the funnel plot and Egger’s regression
test was lacking (P=0.82). In the higher risk group of patients
with ST elevation myocardial infarction undergoing primary
percutaneouscoronaryintervention(n=10243),enoxaparinwas
associated with a significant 48% relative risk reduction in
mortality (3.12% enoxaparin v 6.03% unfractionated heparin)
and a 2.91% absolute relative risk reduction (P<0.001;
NNT=34). Heterogeneity between trials was not significant
(P=0.53) and evidence of publication bias in the primary
percutaneous coronary intervention subgroup was lacking
(P=0.90). In the smaller and lower risk group of patients with
non-STelevationacutecoronarysyndromesandstablecoronary
artery disease undergoing scheduled percutaneous coronary
intervention (relative weight 12.5%; mortality rate 0.88%)
mortality rates did not differ significantly between the
enoxaparin and unfractionated heparin cohorts, with a trend
towards a reduction in mortality with enoxaparin.
Safety outcomes
In the overall cohort of patients with reported major bleeding
(n=30775),enoxaparinwasassociatedwitha20%relativerisk
reduction(0.80,95%confidenceinterval0.67to0.95;P=0.009)
and an absolute risk reduction of 1.20% (NNT=83; fig 4⇓).
Heterogeneity between trials was not significant (P=0.58) and
evidenceofpublicationbiaswaslacking.Thereductioninmajor
bleeding seemed to be greater in patients with ST elevation
myocardial infarction undergoing primary percutaneous
coronary intervention, with enoxaparin treatment compared
with unfractionated heparin treatment resulting in relative and
absolute risk reductions of 28% and 1.9%, respectively
(NNT=53), P=0.01.
Although the incidence of minor bleeding was numerically
lower in patients treated with enoxaparin than with
unfractionated heparin, this difference was not significant in
the overall percutaneous coronary intervention cohort or in the
setting of primary percutaneous coronary intervention (fig 2).
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Compared with unfractionated heparin, enoxaparin was
associatedwitha32%relativeriskreductionand2.01%absolute
risk reduction of death or myocardial infarction (relative risk
0.68,95%confidenceinterval0.57to0.81;P<0.001,NNT=50;
see web extra figure 1). Similarly, enoxaparin was associated
withasignificant25%relativeriskreductionand1.52%absolute
risk reduction in complications of myocardial infarction (0.75,
0.66 to 0.85; P<0.001; NNT=66; see web extra figure 2).
Heterogeneitybetweentrialsforthesetwocompositeendpoints
was not significant (P=0.42 and P=0.55, respectively) and
evidenceofpublicationbiasusingthefunnelplotwasnotfound.
The magnitude of the enoxaparin effect was largest in patients
with ST elevation myocardial infarction undergoing primary
percutaneous coronary intervention, with a 44% relative risk
reduction and a 3.6% absolute risk reduction of death or
myocardial infarction (0.56, 0.42 to 0.76; NNT=28; P<0.001),
with a consistent significant reduction of complications of
myocardial infarction compared with unfractionated heparin
(0.76, 0.60 to 0.96; P=0.022; see web extra figure 1).
Sensitivity and subgroups analyses
Aseriesofsensitivityanalysesconfirmedthesamedirectionality
for the primary efficacy end point (mortality) and the primary
safety end point (major bleeding, tables 2⇓ and 3⇓). None of
the studies individually affected the overall results either for
mortality or for major bleeding. The reduction in mortality
associatedwithenoxaparinwasconsistentacrossallsubgroups,
with the single exception of the subgroup of small sized studies
(<500patients),whichshowedareductionofsimilarmagnitude
that did not reach significance (relative risk 0.59, 95%
confidenceinterval0.20to1.78;P=0.35).Nosubgroupanalyses
showed heterogeneity, and the superiority of enoxaparin on
mortality was significant in both randomised controlled studies
(n=16)andregistrybasedstudies(n=7).Resultswereconsistent
for major bleeding across all subgroups except for route of
administeredenoxaparin.Inthesubgroupofstudies(14studies,
10 260 patients) using intravenous enoxaparin, major bleeding
was reduced by 34% compared with unfractionated heparin
(0.66, 0.52 to 0.83; P<0.001, P for heterogeneity 0.9; absolute
riskreduction1.52%;NNT=66).Thisfavourableeffectwasnot
observed in the subgroup of studies that used subcutaneous
enoxaparin (six studies, 16 527 patients), with no difference
between the two anticoagulants (1.04, 0.80 to 1.35, P=0.7, P
for heterogeneity 0.4). Finally, the arcsine test for binary
outcomesconfirmedtheresultsoftheprimaryadditivesummary
models for all end points.
Discussion
Inthismeta-analysis,enoxaparinwassuperiortounfractionated
heparin in reducing mortality and bleeding outcomes during
percutaneous coronary intervention, particularly in patients
undergoing primary percutaneous coronary intervention for ST
elevation myocardial infarction. Since early 2000 data have
accumulated on enoxaparin in varied percutaneous coronary
intervention settings. This current meta-analysis, with
information on more than 30 000 patients, showed a 34%
statistically significant reduction in mortality (1.66% absolute
risk reduction) in patients receiving enoxaparin during
percutaneous coronary intervention compared with
unfractionated heparin. This survival benefit is supported by
concomitant reductions in both ischaemic and major bleeding
complications. All sensitivity analyses of mortality confirmed
agenuinedifferencebetweenthetwodrugs.Subgroupanalyses
suggested that the benefits on mortality and ischaemic
complications were largely driven by the superiority measured
in patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction, whereas
the better safety outcomes might be driven by the intravenous
(versus subcutaneous) use of enoxaparin.
This meta-analysis confirms the results recently reported in the
ATOLL (Acute ST-elevation myocardial infarction Treated
with primary angioplasty and intravenous enoxaparin Or
unfractionated heparin to Lower ischemic and bleeding events
atshort-andLong-termfollow-up)randomisedtrial.
14Compared
with unfractionated heparin, intravenous enoxaparin at a dose
of 0.5 mg/kg reduced death or resuscitated cardiac death in
patientsundergoingprimarypercutaneouscoronaryintervention
by 42% (P=0.049) and death or myocardial infarction by 37%
(P=0.02).
14Althoughthe40%relativeriskreductioninallcause
mortality associated with enoxaparin in ATOLL was not
significant(P=0.08)owingtolackofpower,itisconsistentwith
the 38% reduction in mortality found in the group with ST
elevation myocardial infarction in the current meta-analysis
(P<0.001), and more specifically with the 48% reduction of
mortalityinpatientsundergoingprimarypercutaneouscoronary
intervention (P<0.001). The survival benefit associated with
enoxaparin was present in both risk of bias subgroups in our
meta-analysis;inlowriskofbiasstudies(randomisedtrialsand
retrospectiveanalysisofrandomisedtrials)andinthoseshowing
higher risk of bias (non-randomised studies).
This reduction in mortality is likely to be related to the
favourable effects of enoxaparin in the prevention of ischaemic
complications, which were also shown in this meta-analysis.
Consistent reductions in ischaemic end points were observed
in the overall analysis as well as in the five largest randomised
studies,
13 14 30 35 42 which together represented two thirds of the
weightofischaemiceventsinourmeta-analysis.Incomparison
with unfractionated heparin, enoxaparin has been shown to be
more stable and have more predictable pharmacokinetics,
1
providing an optimal level of anticoagulation at the time of the
procedure in more than 90% of patients, by whatever route the
drug is administered.
9 49-51 These optimal levels of
anticoagulation have also been related to better ischaemic and
survival outcomes.
10 Moreover, additional endothelial and
anti-inflammatory properties of enoxaparin
6 may play an
additional part in the prevention of ischaemic complications of
acute coronary syndrome.
Improved safety might also contribute to the reduction in
mortality rates. Previous studies have shown that bleeding and
red blood cell transfusion have deleterious effects
52 and have
an effect on ischaemic outcomes as well as on mortality.
53
Therefore the 20% reduction in major bleeding associated with
enoxaparin might also have affected ischaemic and mortality
outcomes. This result is consistent among all subgroups, with
the exception of studies in which subcutaneous enoxaparin was
used in comparison with unfractionated heparin, when no
difference was seen. It seems that the reduction in major
bleedingwasmostlyobservedwithintravenousenoxaparin,but
thePvalueforinteractionwasnotsignificantprobablybecause
of the heterogeneity in risk levels of populations in the two
subgroups (subcutaneous versus intravenous). Indeed, the
intravenous route provides immediate anticoagulation, with
rapid clearance,
49 avoiding exposure to prolonged
anticoagulation after percutaneous coronary intervention, and
in this study was associated with a 34% reduction in major
bleeding (absolute risk reduction 1.52%) compared with
unfractionated heparin. Therefore this meta-analysis confirms
thebenefitofenoxaparinmeasuredintheindividualrandomised
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1(elective angioplasty) and ATOLL
14(primary
angioplasty) studies, with enough power to show a reduction
in mortality. Patients with ST elevation myocardial infarction
obviously gain a large benefit from enoxaparin on ischaemic
end points and mortality. Although favourable, the magnitude
oftheseeffectsseemslessimportantinotherclinicalsituations.
Comparisons with other reviews
Other new anticoagulants have been compared with
unfractionated heparin in the setting of percutaneous coronary
intervention. Bivalirudin alone compared with unfractionated
heparin plus glycoprotein IIb/IIIa inhibitors has consistently
shown improved safety in percutaneous coronary intervention,
associated with a reduction in mortality in one trial.
54-57 Head to
head comparisons of unfractionated heparin alone in
percutaneouscoronaryinterventionhavealsosuggestedabetter
safety profile of bivalirudin, but without significant advantage
on the net clinical benefit or mortality.
58-60 Finally, a recent
meta-analysis of nine trials, totalling almost 30 000 patients,
confirmed the reduction in major bleeding complications from
use of bivalirudin compared with unfractionated heparin, but
failed to show any benefit on mortality, whereas a trend for
higher risk of myocardial infarction was noted.
61 In contrast
with this, a meta-analysis of nine studies, totalling 16 286
patients, comparing low molecular weight heparin with
unfractionated heparin in the setting of percutaneous coronary
intervention for ST elevation myocardial infarction reported a
reduction in both mortality and major bleeding consistent with
our findings.
62
An alternative anticoagulant, the synthetic factor Xa inhibitor
fondaparinux, has been tested in acute coronary syndromes.
63
Results were not favourable in patients with ST elevation
myocardial infarction undergoing primary percutaneous
coronary intervention
64 and the drug has been tested only
sparingly in elective percutaneous coronary intervention.
65 A
significant increase in catheter related thrombosis with
fondaparinux prompted guidelines committees on both sides of
theAtlantictorecommendunfractionatedheparinasadjunctive
treatment at the time of percutaneous coronary intervention.
The recent results of the randomised Fondaparinux Trial With
Unfractionated Heparin During Revascularization in Acute
Coronary Syndromes (FUTURA) suggest that a standard
unfractionatedheparindoseof85IU/kgbolus,withanadditional
bolus if needed to achieve activated clotting time of 300 to 350
seconds, is preferable to a lower dose in patients previously
treated with subcutaneous fondaparinux.
3 In a pooled analysis
of 19 085 patients with acute coronary syndrome invasively
managed,fondaparinuxreducedmajorbleedingcomparedwith
a heparin based strategy, with similar rates of ischaemic events
and no reduction in mortality.
66
Strengths and limitations of this
meta-analysis
Our meta-analysis has limitations and was not carried out on
individual patients’ data, which if possible would have
strengthened the results, especially for subgroup analyses.
Although differences in trial designs and definitions should be
considered when interpreting the overall results, mortality is a
hard end point not affected by study definitions. Duration and
dose of study drugs also differed between trials, as did the use
of concomitant treatments and types of revascularisation. Of
note, many of the non-randomised studies were not pure head
to head comparisons of the two anticoagulants. However, the
absence of heterogeneity in the overall analysis and the
sensitivity and subgroup analyses all showing consistent
reductions in mortality, suggest that the results are robust.
Regarding safety, it seems that the intravenous route for
administeringenoxaparindrivesthereductioninmajorbleeding,
confirming previous information from randomised trials.
11 14 67
Duration of anticoagulation is a possible confounder for this
problem, although this information is usually not available in
published data.
Meaning of the study and implications for
policymakers
Theprofoundreductioninmortalityfoundinthismeta-analysis
could be explained by the additional reductions of serious
ischaemic events and major bleeding. The global reduction in
ischaemic events and mortality was driven by the major effect
observed in the setting of primary percutaneous coronary
intervention for ST elevation myocardial infarction and is in
linewiththeresultsoftheATOLLrandomisedtrial.
14Thiseffect
wasobtainedfromanticoagulationusingintravenousenoxaparin
and the favourable pharmacodynamic profile of the 0.5 mg/kg
dose. A similar benefit on mortality has been seen recently in
other studies of ST elevation myocardial infarction using
bivalirudin
56 or radial access.
68 69 In lower risk populations the
same interventions did not reduce mortality.
1 54 69 The results of
this meta-analysis should influence the next guidelines dealing
with anticoagulation in percutaneous coronary intervention or
in ST elevation myocardial infarction. The superiority of
enoxaparinoverunfractionatedheparinisnowwelldocumented
in the setting of percutaneous coronary intervention, by
randomised controlled trials, registry based studies, and this
meta-analysis, building the case for an update of current
guidelines on anticoagulation. This is particularly true for
primary percutaneous coronary intervention, where the benefit
is most striking.
Unanswered questions and future research
Two new anticoagulants (bivalirudin and enoxaparin) have
proved to be superior to unfractionated heparin during
percutaneouscoronaryintervention,particularlyinpatientswith
ST elevation myocardial infarction undergoing primary
percutaneouscoronaryintervention.Aheadtoheadcomparison
between intravenous enoxaparin and intravenous bivalirudin is
needed in the setting of primary percutaneous coronary
intervention using contemporary techniques (radial access, last
generationofstent,andthromboaspiration)andnewantiplatelet
agents such as prasugrel or ticagrelor.
Conclusions
During percutaneous coronary intervention, enoxaparin seems
to be superior to unfractionated heparin in reducing all cause
mortality and ischaemic and bleeding end points. This
superioritywasparticularlyevidentinpatientswithSTelevation
myocardial infarction undergoing primary percutaneous
coronary intervention. Given the relatively low cost of
enoxaparin (and its wide availability), this seems to be an
attractive strategy to improve outcomes in the large number of
patients undergoing percutaneous coronary intervention
worldwide.
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RESEARCHWhat is already known on this topic
Enoxaparin has a more stable and predictable anticoagulant effect than unfractionated heparin, which requires tight monitoring and
dose adjustment
In randomised studies, intravenous enoxaparin 0.5 mg/kg was superior to unfractionated heparin in elective percutaneous coronary
intervention (reduction of bleeding) and primary percutaneous coronary intervention (reduction of ischaemic events)
What this study adds
Enoxaparin use during percutaneous coronary intervention reduced mortality by 34% (absolute risk reduction 1.66%) compared with
unfractionated heparin
The mortality benefit was particularly noticeable in patients with ST elevation myocardial infarction undergoing primary percutaneous
coronary intervention
This survival benefit is supported by concomitant reductions in both ischaemic and major bleeding complications
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RESEARCHTables
Table 1| Description of studies included in meta-analysis
Follow-up
Study population/PCI
setting
Study design (quality score*or
risk of bias)
No of patients in
enoxaparin/unfractionated
heparin groups Journal Study
1 month Primary PCI (STEMI) Randomised controlled trial (low
risk)
450/460 Lancet ATOLL 2011
14
1 month Primary PCI (STEMI) Registry (8/9) 346/234 Catheter Cardiovascular
Intervention
Brieger et al 2011
16
8 months Primary PCI (STEMI) Registry (9/9) 1531/1841 American Heart Journal Li et al 2010
28
3 months Primary PCI (STEMI) with
33% of patients receiving
half dose thrombolysis
Prospective substudy of
randomised controlled trial (9/9)
759/1693 JACC. Cardiovascular
Interventions
FINESSE Enox 2010
13
In-hospital Primary PCI (STEMI) Registry (6/9) 91/100 Medicina Intensiva Galeote et al 2009
19
15 months Primary PCI (STEMI) Registry (6/9) 39/44 Journal of Thrombosis and
Thrombolysis
Khoobiar et al 2008
29
In-hospital Primary PCI (STEMI) Registry (9/9) 374/2281 Eurointervention Zeymer et al 2008
43
1 month Post-fibrinolysis PCI
(STEMI)
Retrospective analysis of
randomised controlled trial (9/9)
2272/2404 Journal of the American
College of Cardiology
ExTRACT-TIMI 25
2007
34
1 month Post-fibrinolysis PCI
(STEMI)
Retrospective analysis of
randomised controlled trial (9/9)
1429/1431 Circulation CLARITY-TIMI 28
2005
30
12 months Post-fibrinolysis PCI
(STEMI)
Retrospective analysis of
randomised controlled trial (9/9)
590/624 Journal of the American
College of Cardiology
ASSENT-3 2003
32
1 month Elective or urgent PCI Randomised controlled trial (low
risk)
436/440 Eurointervention ZEUS 2010
15
In-hospital Elective or urgent PCI Registry (8/9) 222/271 Texas Heart Institute Journal Diez et al 2009
17
In-hospital Early PCI Registry (8/9) 339/994 American Journal of
Cardiology
Zeymer et al 2006
20
1 month Elective PCI Randomised controlled trial (low
risk)
2298 (2 doses)/1230 New England Journal of
Medicine
STEEPLE 2006
11
1 month Elective or urgent PCI Retrospective analysis of
randomised controlled trial (9/9)
2028/2293 American Heart Journal SYNERGY 2006
31
1 month Elective PCI Randomised controlled trial
(unclear risk)
68/71 Korean Circulation Journal Her et al 2006
21
1 month Elective PCI Randomised controlled trial (low
risk)
100/100 American Journal of
Cardiology
ACTION 2005
22
1 month Elective or urgent PCI Randomised controlled trial (low
risk)
129/132 Journal of the American
College of Cardiology
CRUISE 2003
23
In-hospital Elective or urgent PCI Randomised controlled trial
(unclear risk)
50/49 Revista Espanola de
Cardiologia
Galeote et al 2002
24
1 month Elective PCI Randomised controlled trial
(unclear risk)
50/50 Kardiologia Polska Drozd et al 2001
18
In-hospital Elective or urgent PCI Randomised controlled trial (low
risk)
200/200 American Journal of
Cardiology
Dudek et al 2000
27
In-hospital Elective PCI Randomised controlled trial
(unclear risk)
112 (2 doses)/50 Journal of the American
College of Cardiology
Dudek et al 2000
26
1 month Elective PCI Randomised controlled trial (low
risk)
30/30 American Journal of
Cardiology
Rabah et al 1999
25
PCI=percutaneous coronary intervention; STEMI=ST elevation myocardial infarction.
*Non-randomised controlled trials.
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RESEARCHTable 2| Subgroup analysis for mortality
P values
Relative risk (95% CI)
No of deaths/No in group
No of patients
No of
studies Subgroup
For
heterogeneity Overall
Unfractionated heparin
group Enoxaparin group
0.46 <0.001 0.66 (0.57 to 0.76) 622/17 023 278/13 943 30 966 23 Overall
0.56 <0.001 0.66 (0.56 to 0.77) 621/16 773 278/13 631 30 404 21 Published (full length
report)
0.43 <0.001 0.65 (0.52 to 0.81) 615/15 923 275/12 852 28 778 12 Large size (≥500)
0.46 0.35 0.59 (0.20 to 1.78) 7/1097 3/1091 2188 11 Small size (<500)
0.52 <0.001 0.62 (0.48 to 0.78) 557/11 112 237/7881 18 993 10 Patients with STEMI
0.97 0.006 0.78 (0.66 to 0.93) 325/11 258 211/11 001 22 259 16 High quality studies: RCT*
0.86 <0.001 0.43 (0.33 to 0.57) 297/5765 67/2943 8707 7 Low quality studies:
registries
0.57 0.017 0.70 (0.53 to 0.94) 314/8638 197/7889 16 527 6† Subcutaneous enoxaparin
0.99 0.004 0.66 (0.50 to 0.88) 151/5110 74/5341 10 451 15† Intravenous enoxaparin
STEMI=ST elevation myocardial infarction; RCT=randomised controlled trial.
*Including substudies of RCTs.
†Two studies did not mention mode in which drug was administered.
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RESEARCHTable 3| Subgroup analysis for major bleeding
P values
Relative risk (95%CI)
No with major bleeding/No in group
No of patients
No of
studies Subgroup
For
heterogeneity Overall
Unfractionated heparin
group Enoxaparin group
0.58 0.009 0.80 (0.68 to 0.95) 564/16 923 295/13 852 30 775 22* Overall
0.62 0.022 0.80 (0.66 to 0.96) 564/16 673 295/13 540 30 213 20 Published (full length
report)
0.55 0.041 0.80 (0.50 to 0.99) 549/15 926 288/12 852 28 778 12 Large size (≥500)
0.98 0.26 0.62 (0.27 to 1.42) 15/997 7/1000 1997 10 Small size (<500)
0.44 0.026 0.80 (0.66 to 0.97) 384/11 012 170/7790 18 802 9 Patients with STEMI
0.70 0.11 0.83 (0.66 to 1.04) 299/11 258 226/11 001 22 259 16 High quality studies: RCTs†
0.80 0.026 0.73 (0.55 to 0.96) 265/5665 69/2851 8516 7 Low quality studies: registry
based
0.43 0.75 1.04 (0.80 to 1.35) 154/8638 149/7889 16 527 6 Subcutaneous enoxaparin
0.90 <0.001 0.66 (0.52 to 0.83) 185/5010 114/5250 10 260 14 Intravenous enoxaparin
RCT=randomised controlled trial; STEMI=ST elevation myocardial infarction.
*One study did not report major bleeding in both groups and was excluded from analysis.
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RESEARCHFigures
Fig 1 Flow of studies through review
Fig 2 Pooled event rates and relative risk ratios for major end points in overall cohort of patients undergoing percutaneous
coronary intervention (PCI) and in subgroup of patients undergoing primary percutaneous coronary intervention. STEMI=ST
elevation myocardial infarction
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RESEARCHFig 3 All cause mortality in patients undergoing percutaneous coronary intervention (PCI) treated with enoxaparin or
unfractionated heparin. STEMI=ST elevation myocardial infarction; non-STE ACS=non-ST elevation acute coronary syndrome
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RESEARCHFig 4 Major bleeding in patients undergoing percutaneous coronary intervention (PCI) treated with enoxaparin or
unfractionated heparin. STEMI=ST elevation myocardial infarction; non-STE ACS=non-ST elevation acute coronary syndrome
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